Bericht voor de vakpers

GEA to supply contained tableting lines to top-tier Russian pharmaceutical company

14 Jun 2018

GEA has been chosen by JSC Pharmasyntez, a leading Russian pharmaceutical company, to supply multiple contained tablet manufacturing lines for the production of highly potent hormonal products.

GEA to supply contained tableting lines to top-tier Russian pharmaceutical company

Multi-million euro purchase for three high-containment lines for female and other hormonal preparations finalized at Achema 2018. Right to left Vikram Punia, President JSC PharmaSyntez and Dr. Marcus Michel, Executive Vice President - Head of APC Pharma - GEA Group

Commenting on the multi-million Euro deal, in cooperation with GEA’s representative in Russia, SolidPharma, Phil Gabb, Head of Solid Dosage Sales Support, GEA, said: “We are extremely pleased to be collaborating with Pharmasyntez and, in particular, with Mr Vikram Punia. He has very ambitious growth plans for his company and has a proven track record in achieving his goals.”

GEA will be working with Pharmasyntez to supply and implement three high containment oral solid dosage (OSD) form production lines for female and other hormonal preparations at the company’s Tyumen plant in Siberia. With a planned production capacity of more than a billion tablets per annum, the new facility will benefit from state-of-the-art manufacturing technology from GEA’s batch and continuous portfolio, including single-pot processing solutions — with unique features such as microwave drying and swinging bowl functionality to reduce drying times — MODUL® contained and wash-off-line rotary tablet presses, materials handling systems and MC BUCK® split valve technology. 

A specialist in the development and production of antitubercular, antineoplastic, antiretroviral medicines and hospital antibiotics, Pharmasyntez has a product range of 115 products comprising dosage forms such as tablets, capsules, granules, infusion solutions, sterile powders, and injectables.

“After a stringent review of equipment manufacturers around the globe, Pharmasyntez chose GEA to supply three complete lines - from powder handling to tableting - for its state-of-the-art hormone facility in Tyumen (Russia), said Mr. Vikram Punia.

“When it comes to the production of hormonal pharmaceuticals, there are a lot of critical issues to consider, such as operator safety, dosing, cross-contamination, etc. GEA offered us the best quality solutions for all of the above. We understand that reliable solutions require significant investment, but when it comes to pharma, quality is paramount, which is why we chose GEA,” he added.

“Russian pharma has come a long way in the last seven years, since the introduction of the Pharma 2020 program. Almost USD 5 billion has been invested in the pharma industry, more than 30 new manufacturing facilities have been built and, now, more than 80 per cent of the life-saving drugs used in Russia are made in Russia!”

“Today, more than 90 per cent of the hormone drugs used in the country are imported; Pharmasyntez, supported by the Ministry of Trade and Commerce, and the Institute of Endocrinology, decided to change that. As such, Pharmasyntez has invested more than EUR 50 million in the construction of a modern, GMP-compliant hormone facility.”

“Pharmasyntez would like to thank the Ministry of Trade and Commerce, particularly Mr Denis Manturov, Mr Ivan Dedov from the Institute of Endocrinology and, finally, Mr Vladimir Yakushev from the Tyumen government for their kind support, and VTB (bank) of Russia for financial assistance. The new facility will be one of the largest hormone drug production facilities in Europe, and we look forward to collaborating with current and future partners to improve the production and market access of these life-saving drugs,” he concluded.

In summary, Phil added: “As containment experts, we not only offer the largest variety of solutions for contained processing, but also unrivaled experience in identifying the most appropriate solution based on a containment risk analysis. Plus, from powder to coated tablet, no other supplier offers such as comprehensive range of batch-based and continuous tableting technologies, from powder handling to granulating, drying, compression and coating. This partnership with Pharmasyntez is another shining example of how, at GEA, we’re making science work.”

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

About GEA

GEA is one of the world’s largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services.

With more than 18,000 employees, the group generated revenues of about EUR 5.4 billion in more than 150 countries in the 2023 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customer’s production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company’s purpose: ”Engineering for a better world“. GEA is listed on the German MDAX the European STOXX® Europe 600 Index and is among the companies comprising the DAX 50 ESG, MSCI Global Sustainability as well as Dow Jones Sustainability World and Dow Jones Sustainability Europe Indices.
 
Ontvang nieuws van GEA

Blijf op de hoogte van GEA’s innovaties en verhalen door u in te schrijven op nieuws van GEA.

Neem contact met ons op

Wij zijn er om u te helpen! Met slechts een paar gegevens kunnen we uw vraag beantwoorden.